6
Registered trials
4
Recruiting
6
Unique sponsors
10
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
3
L
Oncology (ATC L)
3
Mechanism of action (INN-stem analysis)
Unknown / small molecule
4 substances
Kinase inhibitor
2 substances
Vinca alkaloid
1 substance
PARP inhibitor
1 substance
Checkpoint inhibitor (PD-1)
1 substance
Monoclonal antibody (immune)
1 substance
Phase III:
4
Phase II:
2
Phase III
4 trials-
EndedBoehringer Ingelheim International GmbH Commercial(3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID
-
RecruitingIntensity Therapeutics Inc. CommercialERIBULIN; PAZOPANIB; TRABECTEDIN; VINBLASTINE SULFATE, CISPLATIN
-
RecruitingEuropean Organisation For Research And Treatment Of Cancer AcademicIMP not specified
-
RecruitingUniversitaet Muenster AcademicTTF-NGR
Phase II
2 trials-
EndedInstitut Gustave Roussy AcademicOLAPARIB; PEMBROLIZUMAB
-
RecruitingRegion Skane AcademicPEMIGATINIB; RETIFANLIMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Commercial | 1 | Phase III | 0 |
| Intensity Therapeutics Inc. | Commercial | 1 | Phase III | 1 |
| Institut Gustave Roussy | Academic | 1 | Phase II | 0 |
| Region Skane | Academic | 1 | Phase II | 1 |
| European Organisation For Research And Treatment Of Cancer | Academic | 1 | Phase III | 1 |
| Universitaet Muenster | Academic | 1 | Phase III | 1 |
New trials by year
2020
1
2021
1
2024
3